Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum

There is increasing evidence implicating HER3 in several types of cancer. But the development of targeted therapies to inactivate HER3 function has been a challenging endeavor. Its kinase domain functions in allostery not catalysis, and the classical ATP-analog class of tyrosine kinase inhibitors fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Saenz, Ana, Sandhu, Manbir, Carrasco, Yazmin, Maglathlin, Rebecca L., Taunton, Jack, Moasser, Mark M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515412/
https://www.ncbi.nlm.nih.gov/pubmed/25619841
http://dx.doi.org/10.1038/onc.2014.455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515412/
https://www.ncbi.nlm.nih.gov/pubmed/25619841
http://dx.doi.org/10.1038/onc.2014.455

Ejemplares similares